📰 Tycel Phillips News
Page 2 - Tycel Phillips News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Tycel Phillips. Real-time updates on events, politics, business and more.
June 9, 2023
Tycel Phillips, MD, hematologist-oncologist at City of Hope in Duarte, CA, discussed the utility of epcoritamab in diffuse large B-cell lymphoma (DLBCL) and the potential impacts the bispecific antibody's recent approval will have in the community oncology setting.
June 8, 2023
Tycel Phillips, MD, MPH, discusses the safety and efficacy of acalabrutinib plus bendamustine and rituximab from a phase 1 trial in patients with treatment-naive and relapsed/refractory mantle cell lymphoma.
June 5, 2023
In this interview, Tycel Phillips, MD, associate professor of medicine, Division of Lymphoma and Bone Marrow Transplantation, City of Hope, Duarte, California, discusses the advancements that are shaping the future of B-cell lymphoma treatment, as well as access barriers.
May 31, 2023
Tycel Phillips, MD, discusses the significance of the FDA approval for epcoritamab in diffuse large B-cell lymphoma, key data from the EPCORE NHL-1 trial that support this approval, and how the approval of epcoritamab signals the expanding role of bispecific antibodies in this patient population.
May 24, 2023
Tycel Phillips, MD, MPH, discusses the implications of the FDA approval of pirtobrutinib in patients with relapsed/refractory mantle cell lymphoma.
May 23, 2023
Tycel Phillips, MD, MPH, discusses treatment options for patients with relapsed/refractory mantle cell lymphoma who have progressed on covalent BTK inhibitors.
May 23, 2023
Tycel Phillips, MD, discusses the significance of the FDA approval of the bispecific antibody epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma.
May 19, 2023
Results from phase 2 clinical trial demonstrated EPKINLY (epcoritamab-bysp) delivered 61 percent overall response rate, 38 percent complete response, and 15.6-month median duration of response in
May 19, 2023
Company Announcement Results from phase 2 clinical trial demonstrated EPKINLY™ delivered 61 percent overall response rate, 38 percent complete response, and 15.6-month median duration of... | May 19, 2023
May 19, 2023
Tycel Phillips, MD, discusses the significance of the FDA approval of the bispecific antibody epcoritamab in patients with relapsed/refractory large B-cell lymphoma.